GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SELLAS Life Sciences Group Inc (FRA:RXK3) » Definitions » EV-to-FCF

SELLAS Life Sciences Group (FRA:RXK3) EV-to-FCF : -2.12 (As of Sep. 20, 2024)


View and export this data going back to 2008. Start your Free Trial

What is SELLAS Life Sciences Group EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, SELLAS Life Sciences Group's Enterprise Value is €63.02 Mil. SELLAS Life Sciences Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €-29.78 Mil. Therefore, SELLAS Life Sciences Group's EV-to-FCF for today is -2.12.

The historical rank and industry rank for SELLAS Life Sciences Group's EV-to-FCF or its related term are showing as below:

FRA:RXK3' s EV-to-FCF Range Over the Past 10 Years
Min: -12.03   Med: -0.39   Max: 0.97
Current: -2.18

During the past 13 years, the highest EV-to-FCF of SELLAS Life Sciences Group was 0.97. The lowest was -12.03. And the median was -0.39.

FRA:RXK3's EV-to-FCF is ranked worse than
100% of 399 companies
in the Biotechnology industry
Industry Median: 8.13 vs FRA:RXK3: -2.18

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-20), SELLAS Life Sciences Group's stock price is €1.074. SELLAS Life Sciences Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.852. Therefore, SELLAS Life Sciences Group's PE Ratio for today is At Loss.


SELLAS Life Sciences Group EV-to-FCF Historical Data

The historical data trend for SELLAS Life Sciences Group's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SELLAS Life Sciences Group EV-to-FCF Chart

SELLAS Life Sciences Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.84 -4.66 -2.59 -1.18 -0.88

SELLAS Life Sciences Group Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -1.36 -0.88 -1.31 -1.87

Competitive Comparison of SELLAS Life Sciences Group's EV-to-FCF

For the Biotechnology subindustry, SELLAS Life Sciences Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SELLAS Life Sciences Group's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where SELLAS Life Sciences Group's EV-to-FCF falls into.



SELLAS Life Sciences Group EV-to-FCF Calculation

SELLAS Life Sciences Group's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=63.019/-29.778
=-2.12

SELLAS Life Sciences Group's current Enterprise Value is €63.02 Mil.
SELLAS Life Sciences Group's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-29.78 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SELLAS Life Sciences Group  (FRA:RXK3) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

SELLAS Life Sciences Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.074/-0.852
=At Loss

SELLAS Life Sciences Group's share price for today is €1.074.
SELLAS Life Sciences Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.852.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


SELLAS Life Sciences Group EV-to-FCF Related Terms

Thank you for viewing the detailed overview of SELLAS Life Sciences Group's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


SELLAS Life Sciences Group Business Description

Traded in Other Exchanges
Address
7 Times Square, Suite 2503, New York, NY, USA, 10036
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

SELLAS Life Sciences Group Headlines

No Headlines